YCANTH for Warts
(COVE-5 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 \[Cantharidin and Occlusion in Verruca Epithelium 5\]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.
Are You a Good Fit for This Trial?
This trial is for people who have common warts, including those around the nails or on the feet. Participants should be generally healthy and able to follow study instructions. Specific inclusion and exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- VP-102
Trial Overview
The study tests a single application of YCANTH (VP-102), a topical treatment applied to warts for 24 hours, to see how safe it is and how much of the drug enters the body. The trial does not use a placebo group.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Topical solution, which is a light violet to dark purple, slightly viscous liquid. Each single-use applicator contains 0.45 mL of 0.7% w/v cantharidin. VP-102 will be administered topically as a single application on Day 1 using no more than 2 applicators.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Verrica Pharmaceuticals Inc.
Lead Sponsor
Veeva Systems
Industry Sponsor
Medidata Solutions
Industry Sponsor
Allucent (US) LLC
Collaborator
Myonex LLC
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.